IL33 and dermatitis: A proof-of-concept clinical study further demonstrated the beneficial therapeutic effects of topical propionate application in mild-to-moderate AD patients, indicating that the sebum–microbial metabolite–IL-33 axis is involved in the pathogenesis of AD, possibly by playing an initiating role in the induction of skin inflammation [119].